Immunovant, INC Form 4 insider transactions

Immunovant CEO Peter Salzmann sold 28,094 shares of common stock on April 9, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Christopher Van Tuyl, Chief Legal Officer of Immunovant, Inc., reports the acquisition of restricted stock units and stock options.

Melanie Gloria, Chief Operating Officer of Immunovant, Inc., reports the acquisition of restricted stock units and stock options.

Jay S. Stout, Chief Technology Officer of Immunovant, Inc., reports transactions involving common stock and stock options, including the acquisition of restricted stock units and stock options, as well as the disposal of common stock.

Michael Geffner, Chief Medical Officer of Immunovant, Inc., reports the acquisition of restricted stock units and stock options.

Eva Renee Barnett, CFO of Immunovant, Inc., reports the acquisition of restricted stock units and stock options, as well as the disposal of common stock.

Peter Salzmann, CEO of Immunovant, Inc., was granted stock options and restricted stock units (RSUs) on April 1, 2025, according to a Form 4 filing.

Director Atul Pande reports acquisition of Immunovant shares and stock options, including restricted stock units, as per Form 4 filing.

Director Douglas J. Hughes reports acquisition of Immunovant stock and stock options on April 1, 2025.

Director Andrew J. Fromkin reports acquisition of restricted stock units and stock options in Immunovant, Inc.

Director George V. Migausky reports acquisition of stock options and restricted stock units in Immunovant, Inc.

Director Frank Torti reports acquiring common stock and stock options in Immunovant, Inc.

Director Andrew J. Fromkin sold shares of Immunovant, Inc. common stock on March 7, 2025, to satisfy tax obligations related to the vesting of restricted stock units.

William L. Macias, Chief Medical Officer of Immunovant, Inc., sold 2,055 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Eva Renee Barnett, CFO of Immunovant, Inc., sold 2,814 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Immunovant CEO Peter Salzmann sold 15,439 shares of common stock on February 19, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Immunovant's Chief Technology Officer, Jay S. Stout, sold 2,195 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Immunovant's Chief Medical Officer, Michael Geffner, sold 2,657 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

William L. Macias, Chief Medical Officer of Immunovant, Inc., sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Immunovant's Chief Financial Officer, Eva Renee Barnett, sold a portion of her shares to cover tax obligations following the vesting of restricted stock units.

Immunovant CEO Peter Salzmann sold shares of common stock on January 15, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Roivant Sciences Ltd., a significant shareholder in Immunovant, Inc., reports acquiring additional shares, increasing its direct ownership.

Eva Renee Barnett, CFO of Immunovant, Inc., sold 4,105 shares of common stock on January 8, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Immunovant CEO Peter Salzmann sold 5,105 shares of common stock on January 8, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Christopher Van Tuyl, Immunovant's Chief Legal Officer, was granted restricted stock units and stock options on December 16, 2024, under the company's 2019 Equity Incentive Plan.

Immunovant director Atul Pande sold 7,750 shares of common stock at a weighted average price of $28.54, pursuant to a pre-arranged 10b5-1 trading plan.

Immunovant director Douglas J. Hughes sold 5,425 shares of common stock at an average price of $28.54, as part of a pre-arranged 10b5-1 trading plan.

Immunovant's Chief Legal Officer, Mark S. Levine, sold 3,650 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Immunovant's Chief Medical Officer, William L. Macias, sold 3,353 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Immunovant's Chief Financial Officer, Eva Renee Barnett, sold 4,174 shares of common stock to cover tax obligations following the vesting of restricted stock units.